18F-meta-fluorobenzylguanidine as a New PET Tracer in Imaging Neuroblastoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Neuroblastoma, a major cause of pediatric cancer deaths, often requires precise imaging for accurate diagnosis and treatment. While 123I-metaiodobenzylguanidine scintigraphy is the current standard for targeting the human norepinephrine transporter (hNET), it has limitations such as low resolution, long scans, and higher radiation exposure. The new PET tracer 18F-meta-fluorobenzylguanidine retains hNET specificity but offers superior image quality, faster acquisition, and lower radiation dose. Clinical studies show improved lesion detection, especially for small or low-uptake metastases, and greater practicality in children. Integration with PET/MR and long axial field-of-view PET/computed tomography further enhances performance and reduces sedation needs.